EDNRA and pulmonary arterial hypertension: Bosentan is the first approved ERA for PAH, a non-peptide pyrimidine derivative that competitively and specifically inhibits ET-1 receptor binding to both ETA and ETB subtypes of receptors, resulting in irreversible blockage of their activities [17].